Key result
Controlling the timing of BCL-2 inhibition is a critical factor in optimizing its potential use as an antifibrotic therapy.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
"Getting the Timing Right: Controlling BCL-2 Inhibition as an Anti-Fibrotic Therapy." American Journal of Respiratory Cell and Molecular Biology, 0(ja), pp.
No takes yet. Share an insight, caveat, or question.
Cooley et al. (2024) studied this question. Controlling the timing of BCL-2 inhibition is a critical factor in optimizing its potential use as an antifibrotic therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: